Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases

Background - Recent advances in digital pathology have enabled accurate and standardised enumeration of tumour-infiltrating lymphocytes (TILs). Here, we aim to evaluate TILs as a percentage electronic TIL score (eTILs) and investigate its prognostic and predictive relevance in cutaneous melanoma. -...

Full description

Saved in:
Bibliographic Details
Main Authors: Chatziioannou, Eftychia (Author) , Roßner, Jana (Author) , Aung, Thazin New (Author) , Rimm, David L. (Author) , Niessner, Heike (Author) , Keim, Ulrike (Author) , Serna-Higuita, Lina Maria (Author) , Bonzheim, Irina (Author) , Kuhn Cuellar, Luis (Author) , Westphal, Dana (Author) , Steininger, Julian (Author) , Meier, Friedegund (Author) , Pop, Oltin Tiberiu (Author) , Forchhammer, Stephan (Author) , Flatz, Lukas (Author) , Eigentler, Thomas (Author) , Garbe, Claus (Author) , Röcken, Martin (Author) , Amaral, Teresa (Author) , Sinnberg, Tobias (Author)
Format: Article (Journal)
Language:English
Published: July 2023
In: EBioMedicine
Year: 2023, Volume: 93, Pages: 1-19
ISSN:2352-3964
DOI:10.1016/j.ebiom.2023.104644
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ebiom.2023.104644
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2352396423002098
Get full text
Author Notes:Eftychia Chatziioannou, Jana Roßner, Thazin New Aung, David L. Rimm, Heike Niessner, Ulrike Keim, Lina Maria Serna-Higuita, Irina Bonzheim, Luis Kuhn Cuellar, Dana Westphal, Julian Steininger, Friedegund Meier, Oltin Tiberiu Pop, Stephan Forchhammer, Lukas Flatz, Thomas Eigentler, Claus Garbe, Martin Röcken, Teresa Amaral and Tobias Sinnberg
Description
Summary:Background - Recent advances in digital pathology have enabled accurate and standardised enumeration of tumour-infiltrating lymphocytes (TILs). Here, we aim to evaluate TILs as a percentage electronic TIL score (eTILs) and investigate its prognostic and predictive relevance in cutaneous melanoma. - Methods - We included stage I to IV cutaneous melanoma patients and used hematoxylin-eosin-stained slides for TIL analysis. We assessed eTILs as a continuous and categorical variable using the published cut-off of 16.6% and applied Cox regression models to evaluate associations of eTILs with relapse-free, distant metastasis-free, and overall survival. We compared eTILs of the primaries with matched metastasis. Moreover, we assessed the predictive relevance of eTILs in therapy-naïve metastases according to the first-line therapy. - Findings - We analysed 321 primary cutaneous melanomas and 191 metastatic samples. In simple Cox regression, tumour thickness (p < 0.0001), presence of ulceration (p = 0.0001) and eTILs ≤16.6% (p = 0.0012) were found to be significant unfavourable prognostic factors for RFS. In multiple Cox regression, eTILs ≤16.6% (p = 0.0161) remained significant and downgraded the current staging. Lower eTILs in the primary tissue was associated with unfavourable relapse-free (p = 0.0014) and distant metastasis-free survival (p = 0.0056). In multiple Cox regression adjusted for tumour thickness and ulceration, eTILs as continuous remained significant (p = 0.019). When comparing TILs in primary tissue and corresponding metastasis of the same patient, eTILs in metastases was lower than in primary melanomas (p < 0.0001). In therapy-naïve metastases, an eTILs >12.2% was associated with longer progression-free survival (p = 0.037) and melanoma-specific survival (p = 0.0038) in patients treated with anti-PD-1-based immunotherapy. In multiple Cox regression, lactate dehydrogenase (p < 0.0001) and eTILs ≤12.2% (p = 0.0130) were significantly associated with unfavourable melanoma-specific survival. - Interpretation - Assessment of TILs is prognostic in primary melanoma samples, and the eTILs complements staging. In therapy-naïve metastases, eTILs ≤12.2% is predictive of unfavourable survival outcomes in patients receiving anti-PD-1-based therapy. - Funding - See a detailed list of funding bodies in the Acknowledgements section at the end of the manuscript.
Item Description:Online veröffentlicht: 7. Juni 2023
Gesehen am 29.08.2023
Physical Description:Online Resource
ISSN:2352-3964
DOI:10.1016/j.ebiom.2023.104644